|
Status |
Public on Jun 26, 2019 |
Title |
FVB_MMTV_Wnt1_121796_Perou |
Sample type |
RNA |
|
|
Channel 1 |
Source name |
Whole Mouse Reference RNA
|
Organism |
Mus musculus |
Characteristics |
tissue: common reference RNA sample for these experiments consisted of total RNA harvested from equal numbers of C57Bl6/J and 129 male and female Day1 pups
|
Extracted molecule |
total RNA |
Extraction protocol |
Total RNA isolated using Qiagen RNeasy Kit
|
Label |
Cy3
|
Label protocol |
not provided
|
|
|
Channel 2 |
Source name |
FVB_MMTV_Wnt1_121796_Perou
|
Organism |
Mus musculus |
Characteristics |
tissue: FVB/n MMTV-Wnt1 mammary tumor
|
Extracted molecule |
total RNA |
Extraction protocol |
Total RNA isolated using Qiagen RNeasy Kit
|
Label |
Cy5
|
Label protocol |
not provided
|
|
|
|
Hybridization protocol |
described in Hu et al., 2005, BioTechniques, 38:121-125
|
Scan protocol |
Fluorescent array images were collected for both Cy3 and Cy5 with an Agilent scanner and image intensity data were extracted and analyzed with Agilent Feature Extraction software
|
Description |
Agilent Feature Extractor Software
|
Data processing |
Data for both channels were Lowess-normalized and then the log(2) ratio was taken
|
|
|
Submission date |
Aug 06, 2018 |
Last update date |
Jun 28, 2019 |
Contact name |
Charles M. Perou |
E-mail(s) |
cperou@med.unc.edu
|
Organization name |
University of North Carolina at Chapel Hill
|
Department |
Professor of Genetics, and Pathology & Laboratory Medicine; Lineberger Comprehensive Cancer Center
|
Street address |
12-044 Lineberger Comprehensive Cancer Center CB# 7295
|
City |
Chapel Hill |
State/province |
NC |
ZIP/Postal code |
27599-7264 |
Country |
USA |
|
|
Platform ID |
GPL11383 |
Series (2) |
GSE118162 |
The MMTV-Wnt1 murine model produces two phenotypically distinct subtypes of mammary tumors with unique therapeutic responses to an EGFR inhibitor (Agilent gene expression) |
GSE118164 |
The MMTV-Wnt1 murine model produces two phenotypically distinct subtypes of mammary tumors with unique therapeutic responses to an EGFR inhibitor |
|